Trial Profile

Efficacy and Safety of Escitalopram in Patients With Generalized Anxiety Disorder; Open-Label, One Arm Postmarketing Study in Russia.

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 09 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Escitalopram (Primary)
Indications Generalised anxiety disorder
Focus Therapeutic Use
Sponsors Lundbeck A/S

Most Recent Events

01 Apr 2010 Actual end date (Mar 2010) added as reported by ClinicalTrials.gov.
01 Apr 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
13 Jan 2010 Planned end date changed from 1 Jan 2010 to 1 Feb 2010 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com